The firm's first candidate, AP003, will focus on rare genetic liver diseases caused by nonsense mutations that prematurely halt protein production.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results